Prime Medicine (PRME) Cash from Operations (2021 - 2026)
Prime Medicine (PRME) reported Cash from Operations of 42710000.0 for Q1 2026, up 12.58% on a YoY basis from 37936922.22 in Q1 2025, and down 14.64% quarter-over-quarter from 37256000.0 in Q4 2025.
Prime Medicine (PRME) Cash from Operations (2021 - 2026) Analysis & Trends
Prime Medicine has reported Cash from Operations for 6 years, with the latest figure at 42710000.0 in Q1 2026.
- For the quarter ending Q1 2026, Cash from Operations rose 12.58% year-over-year to 42710000.0; the trailing twelve-month figure through Mar 2026 stood at 156417000.0 (down 50.38% YoY), and the FY2025 full-year result was 162564000.0, down 32.31% from the prior year.
- Cash from Operations for Q1 2026 stood at 42710000.0, down from 37256000.0 in the prior quarter.
- The five-year high for Cash from Operations was 16245000.0 in Q4 2024, with the low at 67707000.0 in Q1 2024.
- Historically, Cash from Operations has averaged 36786941.18 across 5 years, with a median of 40821000.0 in 2023.
- Annual changes were most pronounced in 2024 — Cash from Operations surged 137.03% — and 2025, when it plunged 329.34%.
- Prime Medicine's Cash from Operations stood at 30713000.0 in 2022, then plunged by 42.82% to 43864000.0 in 2023, then surged by 137.03% to 16245000.0 in 2024, then tumbled by 329.34% to 37256000.0 in 2025, then retreated by 14.64% to 42710000.0 in 2026.
- The last three Cash from Operations figures came in at 42710000.0 (Q1 2026), 37256000.0 (Q4 2025), and 35039000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -1.67 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -12.20 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -2.49 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.43 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Prime Medicine | 572.02 Mn | 572.02 Mn | - | -42.71 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -42.71 Mn |
| Mar 31, 2026 | -42.71 Mn |
| Dec 31, 2025 | -37.26 Mn |
| Dec 31, 2025 | -37.26 Mn |
| Sep 30, 2025 | -35.04 Mn |
| Sep 30, 2025 | -35.04 Mn |
| Jun 30, 2025 | -41.41 Mn |
| Jun 30, 2025 | -41.41 Mn |
| Mar 31, 2025 | -48.86 Mn |
| Mar 31, 2025 | -48.86 Mn |
| Dec 31, 2024 | 16.25 Mn |
| Dec 31, 2024 | 16.25 Mn |
| Sep 30, 2024 | -25.91 Mn |
| Sep 30, 2024 | -25.91 Mn |
| Jun 30, 2024 | -45.49 Mn |
| Jun 30, 2024 | -45.49 Mn |
| Mar 31, 2024 | -67.71 Mn |
| Mar 31, 2024 | -67.71 Mn |
| Dec 31, 2023 | -43.86 Mn |
| Dec 31, 2023 | -43.86 Mn |